Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd
sales@dingminpharma.com
86-311-67591193
Brand: DM
Packaging: double PE with aluminium foil bag
Productivity: 100kg/month
Transportation: Ocean,Air
Place of Origin: Hebei,China
Supply Ability: 100kg/month
Certificate: ISO9001
Port: Shanghai
Payment Type: L/C,T/T,Paypal
Incoterm: FOB,CIF
Darolutamide is a novel androgen receptor (AR) inhibit designed to inhibit the growth of prostate cancer cells through binding to the AR to inhibit the testosterone-induced AR nuclear translocation.
Darolutamide is particularly used in patients with progressive metastatic castration-resistant prostate cancer. It is effective in inhibiting the activity of some mutant ARs emerging during antiandrogen therapies, including the F876L mutation version which is resistant to enzalutamide and ARN-509 (the second-generation antiandrogens). Therefore, it has potential to overcome the resistance issue occurring upon AR-targeted therapies.
| Product Name | Darolutamide |
| Synonyms | ODM-201(Darolutamide);ODM-201;BAY-1841788;N-[(1S)-2-[3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl]-1-methylethyl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide;Darolutamide;N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide;Darolutamide (ODM-201) |
| CAS | 1297538-32-9 |
| MF | C19H19ClN6O2 |
| MW | 398.84616 |
| EINECS | 829-313-8 |
| Product Categories | Inhibitor |
| Mol File | 1297538-32-9.mol |
Product Categories : APIs And Intermediates > APIs Powder
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Contact Now